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Background: The study quantified the relative contributions of estrogen (E2) and total testosterone (TT) to variation
in bone mineral density in men and women.
Methods: This was a cross-sectional study which involved 200 men and 415 women aged 18 to 89 years. BMD at
the lumbar spine (LS) and femoral neck (FN) was measured by DXA. Serum levels of E2 and TT were measured by
electrochemiluminescence immunoassays. The association between E2, TT, and BMD was analyzed by the multiple
linear regression model, adjusting for age and BMI. The contribution of each hormone to the variation in BMD was
quantified by the bootstrap method.
Results: In women, higher serum levels of E2, but not TT, were significantly associated with greater BMD at the FN
(P = 0.001) and LS (P < 0.0001). In men, higher serum levels of E2 were independently associated with greater
FNBMD (P = 0.008) and LSBMD (P = 0.086). In the multiple linear regression model, age, body weight and E2
accounted for 50-55% variance in FNBMD, and 25% (in men) and 48% (in women) variance in LSBMD. Variation in
E2 accounted for 2.5% (95% CI 0.4 - 7.8%) and 11.3% (95% CI 8.1 - 15.3%) variation in FNBMD in men and women,
respectively. Moreover, E2 contributed 1.2% (95% CI 0.1 - 5.8%) and 11.7% (95% CI 8.5 - 15.9%) variation in LSBMD
in men and women, respectively.
Conclusions: Estrogen is more important than testosterone in the determination of age-related bone mineral
density men and women of Vietnamese background. However, the relative contributions of estrogen to bone
mineral density in men are likely modest.
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That estrogen plays a critical role in bone health in women
is a well-known fact. Deficiency of estrogen leads to in-
creased bone loss, lower bone mineral density (BMD), and
increased fracture risk [1]. In women with reduced bone
density and/or an existing fracture, treatment with estro-
gen could reduce bone loss, and lower fracture risk [2].
Thus, the BMD-mediated causal relationship between es-
trogen and fracture in women has been well established.* Correspondence: thuclanhopham@pnt.edu.vn
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reproduction in any medium, provided the orHowever, recently emerging evidence has suggested that
estrogen also has important effects on bone health in men.
Almost 20 years ago, Smith and colleagues reported a 28-
year old man with a bone age of 15 years, who had estrogen
resistance due to disruptive mutation of the estrogen recep-
tor gene [3]. The man had normal level of testosterone and
elevated estradiol, but had severe osteopenia associated
with increased values of bone turnover markers. Subse-
quently, two young men with undetectable estradiol levels
due to mutation in the CYP19A1 gene (this gene is respon-
sible for converting androgens to estrogens) were identified
[4,5]. The two men also had low bone density as initially re-
ported by Smith et al.; however, when the men were treated
with estrogen, their BMD increased. These cases have dem-
onstrated that estrogen does play an important role in theral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the traditional view that estrogen is a “female hormone”.
A series of subsequent case reports have indicated that
estrogen is essential for the normal growth and maturation
of the skeleton in men with aromatase deficiency and low
serum estradiol (E2) levels [4-7]. Some cross-sectional stud-
ies have further demonstrated a significant positive relation-
ship between serum E levels and BMD in men [8-14]. Most
of these studies were based on elderly populations of
Caucasian background, and as a result, it is difficult to
assess the relative contribution of estrogen to the inter-
individual variation in BMD in the general population.
Although these studies collectively suggest that estrogen
might be an important factor for bone growth and bone
maintenance in men, most studies have not considered
the simultaneous effects of estrogen and testosterone on
BMD in men. The question of interest is therefore: what
is the proportion of variation in BMD among men and
women of Asian background that can be attributed to the
variations in estrogen and testosterone. The present study
was designed to address that research question by analyz-
ing the relative contributions of serum levels of estradiol
and testosterone to the variation in BMD in Asian men
and women.
Methods
Study design and participants
The study was designed as a cross-sectional investigation,
with the setting being Ho Chi Minh City, a major city in
Vietnam. The research protocol and procedures were
approved by the Scientific Committee of the People’s
Hospital 115 and Pham Ngoc Thach University of Medi-
cine. All volunteer participants were provided with full in-
formation about the study’s procedures and aims, and
gave informed consent to participate in the study, accord-
ing to the principles of medical ethics of the World Health
Organization and the Helsinki Declaration.
We used simple random sampling technique to identify
potential participants. We approached community organi-
zations, including churches and temples, and obtained the
list of members, and then randomly selected individuals
aged 18 or above. We sent a letter of invitation to the se-
lected individuals. The participants received a free health
check-up, and results of lipid analysis, but did not receive
any financial incentive. Participants were excluded from
the study if they had diseases deemed to affect to bone
metabolism, such as hyperthyroidism, hyperparathyroid-
ism, chronic kidney disease, malabsorption syndrome, al-
coholism, chronic colitis, multiple myeloma, leukemia or
chronic arthritis.
Measurements and data collection
Data collection was done by research doctors and nurses
using a validated questionnaire. The questionnaire solicitesthe following information from participants: anthropomet-
ric factors, lifestyle factors, dietary intakes, physical activity,
and clinical history. Anthropometric parameters including
age, weight, standing height were obtained. Age was calcu-
lated from the date of birth to the date of interview. Height
without shoes (in centimeters) was measured to the near-
est 0.1 cm by a wall-mounted stadiometer. Weight, with-
out shoes or clothing, was measured (to the nearest
0.1 kg) on an electronic scale. Body mass index (BMI) was
then derived as the ratio of weight (kg) over height
squared (in m2).
Bone mineral density
Areal BMD was measured at the lumbar spine (L2-L4),
femoral neck, and whole body using a Hologic QDR 4500
(Hologic Corp, Madison, WI, USA). The short-term in vivo
expressed as the coefficient of variation was 1.8% for the
lumbar spine and 1.5% for the hip. The machine was stan-
dardized by a standard phantom before each measurement.
BMD at femoral neck was used as a main variable for
analysis.
Measurement of sex hormones
Blood samples were collected between 8 AM and 10 AM
after an overnight fast. Serum concentrations of total tes-
tosterone (TT) and estradiol (E2) were measured by elec-
trochemiluminescence immunoassay (ECLIA) on an Roche
Elecsys 10100/201 system (Roche Diagnosis Elecsys). This
method can measure the concentration of estradiol in the
range of 5–4,300 pg/ml (18.4-15781 pmol/L), and total tes-
tosterone in the range of 25–15,000 pg/ml (87–52000
pmol/L). The sensitivity of the assay is 2.18 pg/ml with an
intraassay CV of 6.2% at 34.8 pg/ml and 2.8% at 1018 pg/
ml. The inter-assay CV at these two levels was <20%.
Data analysis
The association between TT, E2, and BMD was analyzed
by the multiple linear regression model, with BMD being
the outcome variable, and TT and E2 predictor variables.
Because both BMD and concentration of E2 or TT change
with age and weight, the analysis was adjusted for the ef-
fects of age and body mass index (BMI). Because the dis-
tribution of E2 and TT was not normally distributed, we
transformed the variables into natural logarithmic scale
before analysis. The statistical significance of each pre-
dictor variable was assessed by the t-test after adjusting
for all other variables in the model. A nominal P value of
0.05 was considered “statistical significance”. The coeffi-
cient of determination (R2) from the most optimal model
was obtained and further analyzed. In order to address the
relative importance of each and combined predictors, we
used the “lmg” method [15] to decompose the overall R2
into individual effect. The R program was used for the
statistical analysis [16] and the package relaimpo within R
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of individual predictor variable.
Results
The study involved 205 men and 432 women, aged be-
tween 18 and 87 years (Table 1). The average age among
men was 44, which was slightly lower than that among
women (48 years). Fifty-one percent of men and 0.7% of
women reported being current smokers. Approximately
20% men and 13% women were obese (body mass index
greater than 25 kg/m2). On average, men had significantly
lower E2 and higher TT concentrations than women. The
mean value of TT was 487 pg/mL in men and 20 pg/mL
in women; and that of E2 was 28 pg/mL and 80 pg/mL in
men and women, respectively.
Sex hormones and age
The relationship between E2 and age in women was de-
scribed by the third-degree polynomial regression model
(Figure 1). As expected, serum levels of estradiol remained
stable between the ages of 18 and 35, followed by a rapid
decrease between the age of 40 and 60. There was no no-
ticeable change in estradiol between the age of 60 and 70
years. In contrast, the serum levels of estradiol in men de-
clined gradually with advancing age, but the magnitude of
decline was modest, with 0.8% per year.
The relationship between age and total testosterone
was also different between sexes. In men, there was no
appreciable change in TT with advancing age. However,
in women, there was a linear decline of total testoster-
one levels with advancing age, with the rate of decrease
being 2.5% per year.
Sex hormones and BMD
In univariate analysis, individuals with higher serum levels
of E2 also had higher BMD at the femoral neck and lumbar
spine in both men and women (Figure 2). There was no ap-
preciable association between total testosterone and BMD
in men, but a positive relationship was observed in women.
For a given age and body weight, men with greater
serum levels of estradiol had greater BMD at the femoralTable 1 Characteristics of 205 men and 432 women
Variable Men Women P-value
N 205 432
Age (yr) 43.8 (18.4) 47.7 (17.1) 0.009
Weight (kg) 61.1 (9.2) 52.2 (7.6) <0.0001
Height (cm) 164.2 (6.6) 153.4 (5.3) <0.0001
Body mass index (kg/m2) 22.7 (3.2) 22.2 (3.0) 0.091
Current smoking 105 (51%) 3 (0.7%) <0.0001
Testosterone (pg/mL) 487 (208) 20 (32) <0.0001
Estradiol (pg/mL) 28 (42) 80 (237) <0.0001
Note: Data are shown in mean and standard deviation (in bracket).neck and lumbar spine (Table 2). In the presence of estra-
diol, total testosterone was not a significant predictor of
BMD in men. In women, estradiol but not total testoster-
one was a significant predictor of BMD. The magnitude of
association between estradiol and BMD in men was com-
parable with (in the case of lumbar spine BMD) or greater
than that (femoral neck BMD) in women. Each standard
deviation lower in log estradiol was associated with
0.032 g/cm2 lower in femoral neck BMD in men; the esti-
mate for women was 0.014 g/cm2.
Analysis of relative importance
Relative importance analysis (Table 3) shows that variation
in serum levels of estradiol “explained” 2.5% (95% CI 0.4
to 7.8%) of variance in femoral neck BMD. However, in
women, the relative contribution of estradiol to BMD vari-
ation was even greater: 11.3% (95% CI 8.1 to 15.3%) for
femoral neck BMD and 11.7% (95% CI 8.5 to 15.9%) for
lumbar spine BMD. In women, the relative contribution of
estradiol to BMD variation was even greater than the con-
tribution of body weight.Discussion
The traditional view of sex hormones and bone health is
that estrogens are the main sex steroids affecting bone
maturation in women, and that androgens are the corre-
sponding sex steroids in men. However, this view has been
challenged by an initial case report [3] and subsequent re-
ports [4,5] which showed that the “female hormone” is ac-
tually important for bone mineralization and bone growth
in men. However, such a relationship has not been well
documented in Asian men, and it is not clear of the mag-
nitude of effect of estrogen in bone mass in men. The
present study on Asian men shows that estrogen, not tes-
tosterone, was an independent determinant of bone dens-
ity. However, the contribution of estrogen to the variance
of bone density in men is likely to be modest.
Our finding of positive association between estradiol
and bone mass in men is largely consistent with previous
studies in Caucasian men. Indeed, several observational
studies in older Caucasian men have shown that circulat-
ing free estrogen or total estradiol, not testosterone, was
associated with bone density [18-20] and bone loss
[14,21-23]. Our finding is also in line with a recent obser-
vation that in Chinese men, low levels of bioavailable E2
were associated with low bone density and greater bone
loss [24]. Our results further show that the magnitude of
association between estradiol and BMD in men was
comparable with or greater than that in women. Col-
lectively, the present data and evidence to date support
the conjecture that estradiol is probably more important
than testosterone as a determinant of bone growth and
bone maintenance in men and women alike.
Figure 1 Association between estradiol (upper panel) and testosterone (below panel) with age in men (red) and women (black).
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known. Deficiency of estrogen leads to an increased osteo-
clastic formation, expanding the remodeling space, in-
creased cortical porosity, and enlarged the resorption area
on trabecular surface [25,26]. The net result of these ef-
fects is bone loss. Indeed, estrogen deficiency is associated
with an increased in bone resorption marker in men [14]
and women [27]. Moreover, treatment of elderly men with
an aromatase inhibitor resulted in increased bone resorp-
tion and decreased bone formation [28]. Treating osteo-
porotic men with selective estrogen receptor modulator
increased femoral neck BMD [29]. Taken together, these
studies suggest that estrogen is causally linked to bone
mass in men, and that estrogen might be more important
for bone health than are declining levels of testosterone.
However, it can not rule out the role of androgens in
maintaining skeletal integrity and bone homeostasis in men.
Testosterone contributes to the initiation of bone resorption
and maintenance of bone formation. Moreover, the majorityof estrogens in elderly men is derived from androgens by
peripheral conversion [30]. The gene involved in the conver-
sion is the CYP19A1 gene. Men with TTTA repeats in the
gene had higher estradiol levels and reduced bone loss than
those with lower number of such repeats [31].
Despite the established relationship between estrogen
and bone density in men, the magnitude of this association
has not been quantified. In this study, by using a sophisti-
cated statistical technique, we were able to estimate that
estradiol explained only 1.2 to 2.5% of between-individual
variation in BMD. The upper estimate of attributable pro-
portion was ~8%. This relative attribution was much lower
than body weight which accounted for 20% of variation in
BMD. Most of the association between body weight and
BMD is due to muscle mass [32,33]. The dominant contri-
bution of body weight and modest attribution of estrogen
imply that in men physical fitness may be more important
than sex hormones as a factor for maintaining bone mass
in the old age.
Figure 2 Association between estradiol (upper panel) and testosterone (lower panel) and BMD in men (red) and women (black), at the
femoral neck (left) and lumbar spine (right).
Table 2 Association between sex hormones and bone mineral density: the linear regression model
Variable Men Women
Coeffcient (SE) P-value Coeffcient (SE) P-value
Femoral neck BMD
Intercept 0.097 (0.105) 0.354 0.443 (0.032) <0.0001
Age −1.152 (0.104) <0.0001 −1.483 (0.121) <0.0001
Age squared 0.023 (0.101) 0.820 −0.268 (0.096) 0.005
Weight 0.07 (0.0008) <0.0001 0.004 (0.0008) <0.0001
Log (testosterone) 0.020 (0.012) 0.090 −0.004 (0.0005) 0.530
Log (estradiol) 0.032 (0.120) 0.008 0.014 (0.004) 0.001
Lumbar spine BMD
Intercept 0.411 (0.131) 0.002 0.554 (0.040) <0.0001
Age −0.293 (0.130) 0.025 −1.360 (0.150) <0.0001
Age squared −0.253 (0.127) 0.048 −0.765 (0.119) <0.0001
Weight 0.007 (0.001) <0.0001 0.004 (0.0006) <0.0001
Log (testosterone) −0.001 (0.015) 0.951 0.006 (0.008) 0.401
Log (estradiol) 0.026 (0.015) 0.086 0.021 (0.005) <0.0001
Note: SE, standard error.
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Table 3 Relative contribution of age, body weight, testosterone, and estradiol levels to variation in bone mineral
density at the femoral neck and lumbar spine
Predictor Men Women
Femoral neck BMD Lumbar spine BMD Femoral neck BMD Lumbar spine BMD
Age 0.331 0.035 0.279 0.194
(0.246 – 0.409) (0.01 – 0.09) (0.227 – 0.331) (0.155 – 0.239)
Weight 0.202 0.204 0.065 0.067
(0.125 – 0.276) (0.120 – 0.294) (0.036 – 0.114) (0.032 – 0.136)
Log (testosterone) 0.003 0.005 0.029 0.031
(0.001 – 0.044) (0.001 – 0.056) (0.1017 – 0.051) (0.017 – 0.054)
Log (estradiol) 0.025 0.012 0.113 0.117
(0.004 – 0.078) (0.001 – 0.058) (0.081 – 0.153) (0.085 – 0.159)
Note: The data are shown in percentage and 95% confidence interval in brackets. For example, age accounted for 33.1% of the variation in femoral neck BMD in
men. In the presence of age, weight, and testosterone, estradiol further accounted for 2.5% of the variation in femoral neck BMD.
Ho-Pham et al. BMC Musculoskeletal Disorders 2013, 14:366 Page 6 of 7
http://www.biomedcentral.com/1471-2474/14/366In our study, serum levels of testosterone in men
remained fairly stable while there was a linear decline of
estradiol levels with advancing age in men with modest
magnitude of decrease. We found perhaps not surprising
that the age-related decrease in estradiol levels in women
was greater than that in men, such that before the age of
50, estradiol concentrations in women was higher than
that in men, but after the age of 50 years, estradiol levels
in women was lower than in men. This finding is consist-
ent with previous studies [21,34-37].
The present results should be interpreted within a num-
ber of potential strengths and weaknesses. The study partic-
ipants were randomly drawn from the general population
which should enhance the findings’ external validity. The
DXA measurement of BMD is considered gold accurate
and reliable, which ensure the study’s internal validity.
Moreover, the technique of measurement of estradiol and
testosterone was based on the novel Elecsys automated
assay, which has been shown to be a precise method for
measuring sex hormones over a wide reportable range in
serum. Indeed, recent studies have shown that measure-
ment of estradiol and testosterone by this method was
highly concordant with the liquid chromatography tandem
mass spectrometry methods [38-40]. Nevertheless, we did
not measure SHBG, free estradiol and free testosterone in
the study. The study was designed as a cross-sectional in-
vestigation, and as a result, no causal inferences could be
made for the observed relationships between estradiol and
bone density. In this study we did not ascertain the phase
of menstrual cycle which could affect the measured
value of estradiol within an individual. However, the
intra-invididual variability was statistically considered
as a component of the random error in the multiple lin-
ear regression model.
Conclusion
In summary, these data suggest that estradiol, but not
testosterone, was a significant determinant of bonemineral density in Asian men and women. However, the
relative contributions of estradiol to the between-individual
variation in bone density is likely to be modest for men.
This finding is consistent with the hypothesis that es-
trogen is a key hormone in the skeletal maturation,
bone mineralization and maintenance of bone mass in
men and women. The finding also provides further
supportive evidence for the “unitary model” of patho-
genesis of osteoporosis [22].Competing interests
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